Australia - engelsk - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - lumacaftor, quantity: 150 mg; ivacaftor, quantity: 188 mg - granules - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; povidone; sodium lauryl sulfate; hypromellose acetate succinate - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - lumacaftor, quantity: 100 mg; ivacaftor, quantity: 125 mg - granules - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; povidone; sodium lauryl sulfate; hypromellose acetate succinate - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 25 mg - granules - excipient ingredients: lactose monohydrate; hypromellose acetate succinate; croscarmellose sodium; sodium lauryl sulfate; silicon dioxide; magnesium stearate; mannitol; sucralose - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have at least one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data(see section 4.4 special warnings and precautions for use, and section 5.1 pharmacodynamic properties).

Canada - engelsk - Health Canada

leo pharma gen, a division of leo pharma inc. - tacrolimus - ointment - 0.1% - tacrolimus 0.1%

Canada - engelsk - Health Canada

leo pharma gen, a division of leo pharma inc. - tacrolimus - ointment - 0.03% - tacrolimus 0.03%

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 75 mg - tablet, film coated - excipient ingredients: hypromellose acetate succinate; sodium lauryl sulfate; microcrystalline cellulose; lactose monohydrate; silicon dioxide; magnesium stearate; carnauba wax; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - trikafta is indicated for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Armenia - engelsk - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

macleods pharmaceuticals ltd. - pyrazinamide - tablets - 400mg

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - lumacaftor, quantity: 75 mg; ivacaftor, quantity: 94 mg - granules - excipient ingredients: croscarmellose sodium; hypromellose acetate succinate; microcrystalline cellulose; povidone; sodium lauryl sulfate - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Saudi-Arabia - engelsk - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

venus remedies limited, india - bleomycin sulfate - powder for solution for injection/infusion - 15 usp units,

Irland - engelsk - HPRA (Health Products Regulatory Authority)

pharmachemie bv - bleomycin sulfate - pdr for soln for injection - 15 u (usp)/vial %v/v